Israel Active

In a study of over 9,000 patients Tel Aviv University researchers used previously ignored “silent mutations” analysis techniques to increase chances of detecting cancer early. They proved that the huge volume of genomic and gene expression data available can help extend survival times and save lives.

Scientists at the Hebrew University of Jerusalem successfully trialed TriCor (fenofibrate see previously) on 15 severely ill Covid patients. 14 were weaned off their ventilators within a week. TriCor targets inflammation-producing lipids produced by the coronavirus.

Israel’s Institute for Biological Research IIBR (see previously) has stated that it has delivered 1,000 doses of its BriLife coronavirus vaccine to Georgia for starting Phase 2 trials. IIBR’s partner, NRx, will lead the trials, expand patient numbers and prepare for Phase 3.

Some 2.3 million Israelis have now had a coronavirus booster. It is 95% effective against infection and available to all Israelis vaccinated over 5 months ago. Serious case numbers have declined and are nearly negligible in those who have been triple-vaccinated. Some 2.5 million children have returned to school.

After Researchers at Tel Aviv University have printed an entire active and viable glioblastoma (brain cancer) tumor using a 3D printer. It includes simulated brain tissue and blood vessel-like tubes through which blood cells can flow and treatments can be (and have been) tested.

Some 1.2 million Israelis have now had a third coronavirus vaccination and wider rollout is imminent. Maccabi Healthcare Services reported 37 (all non-serious) infections in Israelis over 60 who have been triple-vaccinated, compared to 1,064 (many serious) for those who have had only two doses.

Professor Eli Schwartz of Israel’s Sheba Medical Center was unable to publish the results of his successful double-blind trial of ivermectin on 89 coronavirus patients. Interesting reading.

Israel’s SciSparc to commence a Phase 2a clinical trial of its SCI-110 (formerly THX-110) treatment for patients with Alzheimer's disease (AD) and agitation. The study will be conducted at the Israeli Medical Center for Alzheimer's.

Israel’s Nextage Therapeutics is developing technology to deliver to the brain tiny quantities of controversial chemicals, to treat depression and other neurological disorders.

Scientists from Israel’s Weizmann Institute and the Hebrew University of Jerusalem have unveiled how 3-dimensional space is represented in the brain’s “GPS” system. They mapped out how “grid cells” work in bats and the findings have turned the previous theory “on its head”.